Keros Therapeutics, Inc.KROSNASDAQ
Loading
Cost of Revenue Over TimeContracting
Percentile Rank71
5Y CAGR+14.0%
Studio
Year-over-Year Change

Direct costs attributable to producing goods sold

5Y CAGR
+14.0%/yr
Long-term compound
Percentile
P71
Within normal range
vs 5Y Ago
1.9x
Solid growth
Streak
1 yr
Consecutive growthContracting
PeriodValueYoY Change
TTM$1.17M-
2024$0.00-
2023$0.00-
2022$0.00-
2021$0.00-100.0%
2020$605000.00-96.5%
2019$17.35M+71.6%
2018$10.11M-